title: Management of early stage chronic myeloid leukemia: state-of-the-art approach and future perspectives.
abstract: Tyrosin kinase inhibitors (TKI), have dramatically changed the natural history of chronic myeloid leukemia (CML) leading to an impressive increase in overall survival rates and allowing many CML patients to achieve a close-to-normal life expectancy. Unfortunately, there is growing evidence that these drugs are not curative, about 30-35% of the patients who receive imatinib become resistant or discontinue the drug because of side effects; moreover, 15% of all patients become resistant to all TKIs, a condition which represents the biggest challenge in CML treatment. Recent progresses in CML stem cell biology have identified new agents and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives and have highlighted key strategies for treating, and possibly curing, CML in the upcoming years.
authors: Divisione di Ematologia 1, IRCCS Azienda Ospedaliera Universitaria San Martino - IST, Largo Rosanna Benzi, 10 -16132 Genova, Italy. angelomichele.carella@hsanmartino.it.
authors: Federica
authors: F
authors: Galaverna
authors: Chiara
authors: C
authors: Ghiggi
authors: Fabio
authors: F
authors: Guolo
authors: Germana
authors: G
authors: Beltrami
authors: Clara
authors: C
authors: Dellepiane
authors: Livia
authors: L
authors: Giannoni
authors: Andrea
authors: A
authors: Carella
authors: Angelo M
authors: AM
authors: Carella
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D015195:Drug Design; D019008:Drug Resistance, Neoplasm; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases